Intra-Cellular Therapies Inc (ITCI)
72.89
+0.64
(+0.89%)
USD |
NASDAQ |
Oct 04, 16:00
72.86
-0.03
(-0.04%)
After-Hours: 20:00
Intra-Cellular Therapies Shareholders Equity (Annual): 591.42M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 591.42M |
| December 31, 2022 | 656.07M |
| December 31, 2021 | 417.89M |
| December 31, 2020 | 656.86M |
| December 31, 2019 | 195.01M |
| December 31, 2018 | 317.71M |
| Date | Value |
|---|---|
| December 31, 2017 | 454.44M |
| December 31, 2016 | 375.50M |
| December 31, 2015 | 476.24M |
| December 31, 2014 | 120.55M |
| December 31, 2013 | 31.62M |
| March 31, 2013 | -0.0221M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
195.01M
Minimum
2019
656.86M
Maximum
2020
503.45M
Average
591.42M
Median
2023
Shareholders Equity (Annual) Benchmarks
| ACADIA Pharmaceuticals Inc | 431.76M |
| Ionis Pharmaceuticals Inc | 386.69M |
| Madrigal Pharmaceuticals Inc | 405.33M |
| AbbVie Inc | 10.36B |
| Arcus Biosciences Inc | 462.00M |